High-throughput activity based protein profiling - Systematic mapping of covalent drug-protein interactions on a proteome-wide scale
In Part 3 of our three-part Chemoproteomics Master Class Series, we continue to explore real-world applications led by experts actively advancing the field. In this session, Dr. Martin Steger will highlight advances in a scalable screening platform at NEOsphere supporting activity-based proteome profiling. This approach is widely used to hunt for protein reactive sites that can bind ligands and drug molecules. Martin will share practical insights into the power of chemoproteomics for biotechnology companies focused on drug discovery.
Why Attend
- Learn how proteome-wide covalent screening accelerates target identification.
- See real examples of activity-based profiling applied to drug design.
- Get expert advice on integrating chemoproteomic tools into your discovery pipeline.
Presenter: Martin Steger (Head of Degrader Biochemistry, NEOsphere)
Martin Steger, Ph.D., is Head of Degrader Biochemistry and Co-founder of NEOsphere Biotechnologies, developing high-throughput MS-based proteomics platforms. With over 10 years of experience, he pioneered DIA-MS approaches to detect degrader-induced ubiquitination. Formerly at Evotec and MPI with Matthias Mann, he discovered the first LRRK2 marker for Parkinson’s.
Moderator: Brett Larsen (Sr. Marketing Specialist Proteomics, Thermo Fisher Scientific)
Brett Larsen is a leader in chemoproteomics and post-translational modification analysis at Thermo Fisher Scientific. With over 25 years of mass spectrometry experience, he has led proteomics at LTRI Toronto and advanced applications at MDS Proteomics. Brett brings practical expertise in translating complex workflows into real-world discovery.
